S-3

Merus Announces Pricing of Upsized Public Offering of Common Shares

Retrieved on: 
Giovedì, Maggio 30, 2024
Investment, Jefferies, EEA, BMO Capital Markets, Form, Attention, Madison Avenue, BofA Securities, European Economic Area, Telephone, Sale, Communication, Security (finance), Finance, Advertising, Jefferies Group, S-3, SVB Securities, State Street, FSMA, Person, Floor, Prospectus, Guggenheim Partners, File

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”).

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”).
  • Merus also granted the underwriters a 30-day option to purchase up to an additional 1,132,500 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”).
  • All of the shares in the offering are to be sold by Merus.
  • Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering.

McEwen Mining Announces Flow-Through Financing at $14.36 (Cdn$19.59) per Share a 19% Premium to Market

Retrieved on: 
Mercoledì, Maggio 29, 2024
Offering, Security (finance), Gold, Toronto Stock Exchange, University Avenue, COVID-19, Income Tax Act, News, Equity capital markets, New York Stock Exchange, Mining, Suite, Sale, Capital market, MacEwen, Form, S-3, Prospectus, Attention, Annual report, TSX, MUX

TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) (“McEwen”) is pleased to announce it has priced a public financing to fund continued exploration and development at the Fox Complex in the Timmins region of Ontario, primarily focused on exploration drilling and the development of an underground access ramp from surface to mine the gold resources of Stock East and West. This represents the next area of production growth at the Fox Complex.

Key Points: 
  • Total proceeds from the Offering net of placement agents’ fees is expected to be US$20.9 million (Cdn$28,534,000).
  • Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald & Co. is leading a syndicate of placement agents for the Offering.
  • The Offering is being made pursuant to a shelf registration statement on Form S-3 (File No.
  • All forward-looking statements and information made in this news release are qualified by this cautionary statement.

AITX Files FY2024 10-K and Form S-3

Retrieved on: 
Mercoledì, Maggio 29, 2024
Security (finance), Automation, Form 10-K, Form S-3, RMR, Artificial intelligence, Bank statement, Form, Significance, S-3, AI, Annual report, OTC, RAD

Detroit, Michigan, May 29, 2024 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (OTCPK:AITX), a global leader in AI-driven security and productivity solutions for enterprise clients, filed its annual report on Form 10-K with the Securities and Exchange Commission (SEC) for its fiscal year 2024 ended February 29, 2024. AITX is a ‘full SEC reporting’ company that files detailed annual and quarterly reports. Other companies on the OTC often have lower disclosure requirements under ‘Alternate Reporting’ requirements.

Key Points: 
  • AITX is a ‘full SEC reporting’ company that files detailed annual and quarterly reports.
  • The Company has also filed a Form S-3 with the SEC aimed at optimizing its capital-raising efforts.
  • The S-3 filing provides AITX with the flexibility to manage the number of shares sold over time, enabling more strategic funding based on market conditions.
  • Steve Reinharz, CEO/CTO of AITX, stated, “Our recent market cap increases in May allowed us to be eligible to file the Form S-3.

Merus N.V. Announces Proposed Public Offering of Common Shares

Retrieved on: 
Martedì, Maggio 28, 2024
Investment, Jefferies, EEA, BMO Capital Markets, Form, Attention, Madison Avenue, BofA Securities, European Economic Area, Telephone, Sale, Communication, Security (finance), Finance, Advertising, Jefferies Group, S-3, SVB Securities, State Street, FSMA, Person, Floor, Prospectus, Guggenheim Partners, File

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”).

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of $300,000,000 of its common shares (the “Offer Shares”).
  • All of the common shares are being offered by Merus.
  • In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”).
  • Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering.

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Venerdì, Maggio 24, 2024
Security (finance), BofA Securities, Intellectual property, RBC Capital Markets, CATX, Equity capital markets, Therapy, Telephone, Sale, Capital market, Form, S-3, Prospectus, Cancer, Broad Street, Attention, Vesey Street, RBC, Perspective

The aggregate gross proceeds from this offering are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering.

Key Points: 
  • The aggregate gross proceeds from this offering are expected to be approximately $80 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering.
  • The purchase price per share of each pre-funded warrant represents the per share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant.
  • The offering is expected to close on or about May 29, 2024, subject to the satisfaction of customary closing conditions.
  • All of the shares of common stock and pre-funded warrants to be sold in the offering are being sold by Perspective.

Akoustis Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Mercoledì, Maggio 22, 2024
IDM, Security (finance), Sale, Form, S-3, Prospectus, Roth Capital Partners, BAW

The offering is expected to close on or about May 24, 2024 subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about May 24, 2024 subject to the satisfaction of customary closing conditions.
  • Roth Capital Partners is acting as the exclusive placement agent for the offering.
  • Akoustis expects the gross proceeds from the offering to be approximately $10,000,000 million, before deducting the placement agent’s fees and other estimated offering expenses payable by Akoustis.
  • Akoustis intends to use the net proceeds from the proposed offering for working capital and to fund operations.

Perma-Fix Announces Pricing of Approximately $20 Million Registered Direct Offering

Retrieved on: 
Mercoledì, Maggio 22, 2024
Security (finance), PFAS, Ecosystem, Suite, Sale, Form, S-3, Prospectus, Capital Group Companies

The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $20 million.

Key Points: 
  • The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $20 million.
  • Craig-Hallum Capital Group LLC and Wellington Shields & Co. LLC are acting as exclusive placement agents for the offering.
  • The offering is expected to close on or about May 24, 2024, subject to the satisfaction of customary closing conditions.
  • A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov .

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Retrieved on: 
Lunedì, Maggio 20, 2024
Regulation D, The Act, Parkinson's disease, Exercise, Therapy, Telephone, Sale, Form, S-3, Prospectus, Attention, Security (finance)

The Company has also entered into a warrant inducement agreement with the investor to exercise certain outstanding warrants that the Company issued in January 2023.

Key Points: 
  • The Company has also entered into a warrant inducement agreement with the investor to exercise certain outstanding warrants that the Company issued in January 2023.
  • The gross proceeds to the Company from the registered direct offering, concurrent private placement and warrant inducement are estimated to be approximately $4.0 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company.
  • The offering is expected to close on or about May 22, 2024, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement relating to the shares of common stock and pre-funded warrants will be filed by the Company with the SEC.

Arq Announces $15 Million PIPE Transaction

Retrieved on: 
Giovedì, Maggio 16, 2024
Carbon, S-3, Into, PIPE, GAC, Sale, Form, Cryptocurrency

GREENWOOD VILLAGE, Colo., May 16, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced that it has entered into a transaction with a new institutional accredited investor for the issuance and sale of approximately $15 million of common stock (the "PIPE"). The PIPE was priced at $7.00 per share, which will result in the issuance of 2,142,858 million new common equity shares in Arq, and a total ownership stake of 5.7% in the Company on a fully diluted basis.

Key Points: 
  • Entered Into $15 million PIPE at $7.00 per share, reflecting a roughly 3% discount to yesterday's close
    Transaction resulted from unsolicited offer from new, accredited institutional investor
    GREENWOOD VILLAGE, Colo., May 16, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced that it has entered into a transaction with a new institutional accredited investor for the issuance and sale of approximately $15 million of common stock (the "PIPE").
  • The PIPE was priced at $7.00 per share, which will result in the issuance of 2,142,858 million new common equity shares in Arq, and a total ownership stake of 5.7% in the Company on a fully diluted basis.
  • Following closing of the transaction, Arq will have approximately 36.0 million shares issued and outstanding.
  • We believe this transaction reflects an extremely attractive and accretive financing that further de-risks our strategic investment at Red River.

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

Retrieved on: 
Martedì, Maggio 14, 2024
Insurance, Biomarker, Patient, PARP, Ovarian cancer, FDA, Therapy, Optimism, S-3, Form S-1, ATM, Research, Administration, Outline, Pharmaceutical industry

"The start of 2024 has been a pivotal period for Allarity Therapeutics, marked by significant achievements across financial, regulatory, and clinical areas," remarked Thomas Jensen, CEO of Allarity Therapeutics.

Key Points: 
  • "The start of 2024 has been a pivotal period for Allarity Therapeutics, marked by significant achievements across financial, regulatory, and clinical areas," remarked Thomas Jensen, CEO of Allarity Therapeutics.
  • Reflecting this new strengthened financial position, we have requested the SEC to withdraw our Form S-1 filed last October.
  • Allarity Therapeutics now has a single class of shares after investor-initiated conversions of all outstanding Series A Preferred Stock and the majority of warrants into common stock.
  • Net Loss: Net loss was $3.8 million for the quarter ended March 31, 2024, compared to $3.4 million for the quarter ended March 31, 2023.